APUS
Apimeds·AMEX
--
--(--)
--
--(--)
APUS fundamentals
During Q3 2025, Apimeds (APUS) reported revenue of --, a YoY change of 0.00%. Net income was -1.78M, a YoY change of -435.68%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | TTM |
|---|
Start Date | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | -- |
End Date | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Operating Expenses | 66.19K -- | 56.38K -- | 27.83K -- | 104.16K -- | 559.07K +744.70% | 271.73K +381.94% | 427.76K +1437.26% | 300.00K +188.03% | 275.61K -50.70% | 364.37K +34.09% | 2.66M +522.76% | 1.84M +514.75% | 5.15M -- |
Selling, General and Administrative Expenses | 4.07K -- | 5.83K -- | 5.38K -- | 107.16K -- | 530.52K +12934.89% | 271.73K +4560.82% | 427.76K +7843.49% | 300.00K +179.96% | 275.61K -48.05% | 364.37K +34.09% | 2.01M +370.39% | 1.22M +308.18% | 3.88M -- |
General and Administrative Expenses | 271.53K -- | -- -- | -- -- | 118.37K -- | 530.52K +95.38% | 271.73K -- | 427.76K -- | 300.00K +153.44% | 275.61K -48.05% | 364.37K +34.09% | 2.01M +370.39% | 1.22M +308.18% | 3.88M -- |
Research and Development Expenses | 62.12K -- | 50.55K -- | 22.44K -- | -3.00K -- | 28.55K -54.04% | 0 -100.00% | 0 -100.00% | 0 +100.00% | 0 -100.00% | 0 -- | 651.78K -- | 619.69K -- | 1.27M -- |
Operating Income | -66.19K -- | -56.38K -- | -27.83K -- | -104.16K -- | -559.07K -744.70% | -271.73K -381.94% | -427.76K -1437.26% | -300.00K -188.03% | -275.61K +50.70% | -364.37K -34.09% | -2.66M -522.76% | -1.84M -514.75% | -5.15M -- |
Non-Operating Income (Loss) | -8.41K -- | -8.25K -- | -8.25K -- | -5.86K -- | -7.89K +6.10% | -24.75K -199.96% | -21.61K -161.89% | -32.52K -454.70% | -36.02K -356.24% | -38.03K -53.67% | 1.71K +107.92% | 62.98K +293.67% | -9.35K -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | 9.52K -- | 12.86K -- | -- -- |
Net Interest Expense | 8.41K -- | 8.25K -- | 8.25K -- | 5.86K -- | 7.89K -6.10% | 24.75K +199.96% | 21.61K +161.89% | 32.52K +454.70% | 36.02K +356.24% | 38.03K +53.67% | 7.81K -63.87% | -50.13K -254.13% | 31.73K -- |
Interest Expense | 8.41K -- | 8.25K -- | 8.25K -- | 8.09K -- | 13.48K +60.30% | 26.91K +226.16% | 22.12K +168.16% | 32.64K +303.39% | 36.05K +167.47% | 38.03K +41.34% | 23.05K +4.21% | 6.30K -80.69% | 103.44K -- |
Interest Income | 0 -- | -- -- | -- -- | 2.23K -- | 5.58K -- | 2.16K -- | 517 -- | 116 -94.79% | 30 -99.46% | 3 -99.86% | 15.25K +2849.13% | 56.43K +48543.10% | 71.71K -- |
Pretax Income From Continuing Operations | -74.59K -- | -64.63K -- | -36.08K -- | -110.02K -- | -566.97K -660.07% | -296.47K -358.71% | -449.36K -1145.60% | -332.52K -202.24% | -311.63K +45.03% | -402.40K -35.73% | -2.66M -492.44% | -1.78M -435.68% | -5.16M -- |
Net Income | -74.59K -- | -64.63K -- | -36.08K -- | -110.02K -- | -566.97K -660.07% | -296.47K -358.71% | -449.36K -1145.60% | -332.52K -202.24% | -311.63K +45.03% | -402.40K -35.73% | -2.66M -492.44% | -1.78M -435.68% | -5.16M -- |
Net Income Attributable to Owners of the Company | -74.59K -- | -64.63K -- | -36.08K -- | -110.02K -- | -566.97K -660.07% | -296.47K -358.71% | -449.36K -1145.60% | -332.52K -202.24% | -311.63K +45.03% | -402.40K -35.73% | -2.66M -492.44% | -1.78M -435.68% | -5.16M -- |
Net Income Attributable to Common Stockholders | -74.59K -- | -64.63K -- | -36.08K -- | -110.02K -- | -566.97K -660.07% | -296.47K -358.71% | -449.36K -1145.60% | -332.52K -202.24% | -311.63K +45.03% | -402.40K -35.73% | -2.66M -492.44% | -1.78M -435.68% | -5.16M -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -449.36K -- | -332.52K -- | 1.08M -- | -- -- | -2.66M -492.44% | -1.78M -435.68% | -- -- |
Basic EPS | -- -- | -0.01 -- | -- -- | -- -- | -- -- | -0.04 -300.00% | -0.06 -- | -0.04 -- | -- -- | -0.05 -25.00% | -0.26 -333.33% | -0.14 -250.00% | -- -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -0.04 -- | -- -- | -0.04 -- | -- -- | -0.05 -25.00% | -- -- | -0.14 -250.00% | -- -- |
Diluted EPS | -- -- | -0.01 -- | -- -- | -- -- | -- -- | -0.04 -300.00% | -0.06 -- | -0.04 -- | -- -- | -0.05 -25.00% | -0.26 -333.33% | -0.14 -250.00% | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -0.04 -- | -- -- | -0.04 -- | -- -- | -0.05 -25.00% | -- -- | -0.14 -250.00% | -- -- |
You can ask Aime
What guidance did Apimeds's management provide for the next earnings period?What does Apimeds do and what are its main business segments?What factors drove the changes in Apimeds's revenue and profit?What is Apimeds's gross profit margin?What is Apimeds's latest dividend and current dividend yield?What were the key takeaways from Apimeds's earnings call?What were the key takeaways from Apimeds’s earnings call?Did Apimeds beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
